Japan Tissue Engineering Co., Ltd. (7774.T)
JPY 457.0
(-2.35%)
JPY 457.0
(-2.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 908.43 Million JPY | -3.99% |
| 2022 | 946.14 Million JPY | 1.55% |
| 2021 | 931.66 Million JPY | -2.42% |
| 2020 | 954.78 Million JPY | 16.36% |
| 2019 | 820.53 Million JPY | -1.6% |
| 2018 | 833.85 Million JPY | 8.06% |
| 2017 | 771.64 Million JPY | 42.57% |
| 2016 | 541.22 Million JPY | -6.43% |
| 2015 | 578.42 Million JPY | 26.83% |
| 2014 | 456.07 Million JPY | -57.35% |
| 2013 | 1.06 Billion JPY | 21.08% |
| 2012 | 883.12 Million JPY | -19.92% |
| 2011 | 1.1 Billion JPY | -17.93% |
| 2010 | 1.34 Billion JPY | -13.64% |
| 2009 | 1.55 Billion JPY | 50.38% |
| 2008 | 1.03 Billion JPY | 30.21% |
| 2007 | 794.77 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 761.03 Million JPY | -16.23% |
| 2024 Q2 | 632.18 Million JPY | -16.93% |
| 2023 Q1 | 950.17 Million JPY | 0.43% |
| 2023 Q3 | 977.33 Million JPY | 14.86% |
| 2023 FY | 908.43 Million JPY | -3.99% |
| 2023 Q2 | 850.88 Million JPY | -10.45% |
| 2023 Q4 | 908.43 Million JPY | -7.05% |
| 2022 Q4 | 946.14 Million JPY | 7.92% |
| 2022 Q3 | 876.72 Million JPY | -0.23% |
| 2022 Q2 | 878.76 Million JPY | -7.34% |
| 2022 Q1 | 948.33 Million JPY | 1.79% |
| 2022 FY | 946.14 Million JPY | 1.55% |
| 2021 Q4 | 931.66 Million JPY | 20.0% |
| 2021 Q3 | 776.41 Million JPY | -8.26% |
| 2021 Q2 | 846.34 Million JPY | -1.87% |
| 2021 Q1 | 862.43 Million JPY | -9.67% |
| 2021 FY | 931.66 Million JPY | -2.42% |
| 2020 FY | 954.78 Million JPY | 16.36% |
| 2020 Q2 | 800.53 Million JPY | -1.96% |
| 2020 Q3 | 760.34 Million JPY | -5.02% |
| 2020 Q4 | 954.78 Million JPY | 25.57% |
| 2020 Q1 | 816.5 Million JPY | -0.49% |
| 2019 Q1 | 716.21 Million JPY | -14.11% |
| 2019 Q2 | 621.75 Million JPY | -13.19% |
| 2019 Q3 | 674.02 Million JPY | 8.41% |
| 2019 FY | 820.53 Million JPY | -1.6% |
| 2019 Q4 | 820.53 Million JPY | 21.74% |
| 2018 FY | 833.85 Million JPY | 8.06% |
| 2018 Q2 | 689.88 Million JPY | -26.23% |
| 2018 Q1 | 935.16 Million JPY | 21.19% |
| 2018 Q3 | 737.41 Million JPY | 6.89% |
| 2018 Q4 | 833.85 Million JPY | 13.08% |
| 2017 Q4 | 771.64 Million JPY | 33.23% |
| 2017 FY | 771.64 Million JPY | 42.57% |
| 2017 Q3 | 579.18 Million JPY | 1.02% |
| 2017 Q2 | 573.34 Million JPY | 2.77% |
| 2017 Q1 | 557.87 Million JPY | 3.08% |
| 2016 FY | 541.22 Million JPY | -6.43% |
| 2016 Q2 | 515.1 Million JPY | -8.22% |
| 2016 Q3 | 628.62 Million JPY | 22.04% |
| 2016 Q4 | 541.22 Million JPY | -13.9% |
| 2016 Q1 | 561.24 Million JPY | -2.97% |
| 2015 Q1 | 509.8 Million JPY | 11.78% |
| 2015 FY | 578.42 Million JPY | 26.83% |
| 2015 Q4 | 578.42 Million JPY | 1.02% |
| 2015 Q3 | 572.57 Million JPY | 9.21% |
| 2015 Q2 | 524.27 Million JPY | 2.84% |
| 2014 Q3 | 1.25 Billion JPY | 2.83% |
| 2014 Q2 | 1.21 Billion JPY | 14.44% |
| 2014 FY | 456.07 Million JPY | -57.35% |
| 2014 Q1 | 1.06 Billion JPY | -0.52% |
| 2014 Q4 | 456.07 Million JPY | -63.56% |
| 2013 Q3 | 1.02 Billion JPY | -4.17% |
| 2013 FY | 1.06 Billion JPY | 21.08% |
| 2013 Q2 | 1.06 Billion JPY | 19.17% |
| 2013 Q4 | 1.06 Billion JPY | 4.8% |
| 2013 Q1 | 893.37 Million JPY | 1.16% |
| 2012 Q2 | 986.42 Million JPY | -9.11% |
| 2012 Q1 | 1.08 Billion JPY | -1.59% |
| 2012 Q3 | 952.44 Million JPY | -3.44% |
| 2012 Q4 | 883.12 Million JPY | -7.28% |
| 2012 FY | 883.12 Million JPY | -19.92% |
| 2011 Q2 | 1.23 Billion JPY | -6.5% |
| 2011 Q3 | 1.18 Billion JPY | -4.25% |
| 2011 Q4 | 1.1 Billion JPY | -6.58% |
| 2011 FY | 1.1 Billion JPY | -17.93% |
| 2011 Q1 | 1.31 Billion JPY | -1.87% |
| 2010 Q2 | 1.77 Billion JPY | -4.1% |
| 2010 FY | 1.34 Billion JPY | -13.64% |
| 2010 Q3 | 1.45 Billion JPY | -18.2% |
| 2010 Q4 | 1.34 Billion JPY | -7.36% |
| 2010 Q1 | 1.84 Billion JPY | 18.83% |
| 2009 Q4 | 1.55 Billion JPY | -3.88% |
| 2009 Q2 | 1.6 Billion JPY | 3.84% |
| 2009 Q1 | 1.54 Billion JPY | 49.73% |
| 2009 Q3 | 1.61 Billion JPY | 0.63% |
| 2009 FY | 1.55 Billion JPY | 50.38% |
| 2008 Q4 | 1.03 Billion JPY | 40.11% |
| 2008 FY | 1.03 Billion JPY | 30.21% |
| 2008 Q3 | 738.59 Million JPY | 0.0% |
| 2007 FY | 794.77 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 72.022% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -1332.608% |
| GNI Group Ltd. | 26.34 Billion JPY | 96.551% |
| Linical Co., Ltd. | 10.3 Billion JPY | 91.184% |
| Trans Genic Inc. | 3.81 Billion JPY | 76.173% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -53.918% |
| Soiken Holdings Inc. | 697.02 Million JPY | -30.33% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 69.927% |
| AnGes, Inc. | 2.78 Billion JPY | 67.432% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -76.873% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 98.995% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -157.148% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 44.94% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -92.32% |
| CanBas Co., Ltd. | 91.98 Million JPY | -887.554% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 16.933% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -12.176% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -53.004% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 78.646% |
| PeptiDream Inc. | 29.11 Billion JPY | 96.88% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -60.359% |
| Ribomic Inc. | 155.8 Million JPY | -483.041% |
| SanBio Company Limited | 2.25 Billion JPY | 59.713% |
| Healios K.K. | 11.28 Billion JPY | 91.951% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -261.537% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -146.187% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -276.167% |
| StemRIM | 187 Million JPY | -385.792% |
| CellSource Co., Ltd. | 677.73 Million JPY | -34.038% |
| FunPep Company Limited | 189.32 Million JPY | -379.829% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -52.177% |
| Stella Pharma Corporation | 1.44 Billion JPY | 37.072% |
| TMS Co., Ltd. | 97.68 Million JPY | -829.921% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -892.886% |
| Cuorips Inc. | 200.96 Million JPY | -352.043% |
| K Pharma,Inc. | 209.13 Million JPY | -334.377% |
| Takara Bio Inc. | 11.42 Billion JPY | 92.045% |
| ReproCELL Incorporated | 741.03 Million JPY | -22.59% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 1.011% |
| StemCell Institute Inc. | 3.85 Billion JPY | 76.407% |
| CellSeed Inc. | 301.04 Million JPY | -201.757% |